

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dormisan 1 mg/ml solution for injection for dogs and cats [ES, IT]

Sedalgan 1 mg/ml solution for injection for dogs and cats [PT]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

medetomidine hydrochloride 1.0 mg
(equivalent to medetomidine 0.85 mg)

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
methyl parahydroxybenzoate (E218)	1.0 mg
propyl parahydroxybenzoate	0.2 mg
sodium chloride	
water for injections	

Clear and colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs and cats.

3.2 Indications for use for each target species

In dogs and cats:

- Sedation in order to facilitate the restraint of animals during clinical examinations.
- Premedication prior to general anaesthesia.

3.3 Contraindications

Do not use in animals with serious cardiovascular disease, respiratory disease or hepatic or renal disorders.

Do not use in case of mechanical disorders of gastrointestinal tract (torsion of the stomach, imprisonment, obstruction of the oesophagus).

Do not use in conjunction with sympathomimetic amines.

Do not use in cases of hypersensitivity to the active substance, or to any of the excipients.

Do not use in animals with diabetes mellitus.

Do not use in animals with state of shock, emaciation or serious debilitation.

Do not use in animals with ocular problems where an increase in intraocular pressure would be detrimental.

Do not use in animal with decreased liver function.

See section 3.7.

3.4 Special warnings

It is possible that medetomidine does not provide analgesia throughout the entire sedation period. The use of additional analgesics should be considered during painful surgical procedures.

3.5 Special precautions for use

Special precautions for safe use in the target species:

A clinical examination should be carried out in all animals before the use of veterinary medicinal products for sedation and/or general anaesthesia.

During its use in premedication, the dosage of anaesthetic will be reduced in proportion and established according to the reaction of the animal, depending on the variability of response between animals. Special warnings and contraindications included in the literature of the other veterinary medicinal products should be respected before carrying out any association.

Medetomidine can produce respiratory depression; in such case, manual ventilation and administration of oxygen may be conducted.

Higher doses of medetomidine should be avoided in large breed dogs. Care should be taken when combining medetomidine with other anaesthetics or sedatives because of its marked anaesthetic sparing effects. Animals should be fasted 12 hours before anaesthesia.

The animal should be placed in a calm and quiet surrounding to let the sedation gain its maximum effect. This takes about 10-15 minutes. One should not start any procedure or give other veterinary medicinal products before maximum sedation is reached.

Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.

The eyes should be protected by a suitable lubricant.

Nervous, aggressive or excited animals should be given the possibility to calm down before initiation of treatment.

Sick and debilitated dogs and cats should only be premedicated with medetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.

Care should be taken with use of medetomidine in animals with cardiovascular disease, or which are elderly or in general poor health. Liver and kidney function should be evaluated prior to use.

In order to reduce the recovery time after anaesthesia or sedation, the effect of medetomidine can be reversed by the administration of an alpha-2-antagonist such as atipemazole.

Atipemazole does not reverse the effect of ketamine. As ketamine alone can elicit cramps, alpha-2 antagonists should not be given less than 30-40 min. after the administration of ketamine.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Medetomidine is a sedative and sleep-inducing drug. Care should be taken to avoid self-injection. In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet or the label to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur.

Avoid skin, eye or mucosal contact.

In case of skin or mucosal contact, wash the exposed skin immediately after exposure with large amounts of water.

Remove contaminated clothes that are in direct contact with skin.

In the case of accidental contact of the veterinary medicinal product with eyes, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.

Pregnant women should administer the product with special caution to avoid self-injection since uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.

Advice to doctors:

Medetomidine is an alpha2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported.

Respiratory and haemodynamic symptoms should be treated symptomatically.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs and cats:

Undetermined frequency (cannot be estimated from the available data)*	Bradycardia, heart block 1 st degree, heart block 2 nd degree, extrasystole, vasoconstriction of coronary artery, decreased cardiac output ^a , high blood pressure ^b . Vomiting ^c . Increased sensitivity to sound, tremor. Frequent urination. Hypothermia, cyanosis. Respiratory depression ^a , pulmonary oedema. Injection site pain. Hyperglycaemia ^d .
---	---

^a in cases of cardiovascular and respiratory depression, assisted ventilation and administration of oxygen may be indicated. Atropine can increase the cardiac rate.

^b just after the administration of product and then return to the normal value or slightly below.

^c in some dogs and most cats 5-10 minutes after injection. Cats may also vomit on recovery.

^d reversible, due to depression of insulin secretion.

*Dogs weighing less than 10 kg can present frequently with the above-mentioned adverse reactions.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore, do not use during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction

The concomitant administration of other central nervous system depressants should be expected to potentiate the effect of either veterinary medicinal product and appropriate dose adjustment should be made.

Medetomidine has marked anaesthetic sparing effects (see section 3.5 of the SPC).

The effects of medetomidine can be antagonised by the administration of atipamezole.

Do not administer concomitantly with sympathomimetics or sulfamides and trimethoprim.

3.9 Administration routes and dosage

Dogs: intramuscular or intravenous use

For sedation:

For sedation the veterinary medicinal product should be administered at the rate of 15-80 µg of medetomidine hydrochloride per kg of body weight I.V., or 20-100 µg of medetomidine hydrochloride per kg of body weight I.M.

Use the table below to determine the correct dosage on the basis of body weight.

Maximal effect is obtained within 15-20 minutes. Clinical effect is dose-dependent, lasting 30 to 180 minutes.

The veterinary medicinal product dosages in ml and corresponding amount of medetomidine hydrochloride in µg /kg bw:

body weight [kg]	i.v.- Injection		i.m.- Injection	
	[ml]	corresp. to [µg/kg bw]	[ml]	corresp. to [µg/kg bw]
1	0.08	80.0	0.10	100.0
2	0.12	60.0	0.16	80.0
3	0.16	53.3	0.21	70.0
4	0.19	47.5	0.25	62.5
5	0.22	44.0	0.30	60.0
6	0.25	41.7	0.33	55.0
7	0.28	40.0	0.37	52.9
8	0.30	37.5	0.40	50.0
9	0.33	36.7	0.44	48.9
10	0.35	35.0	0.47	47.0
12	0.40	33.3	0.53	44.2
14	0.44	31.4	0.59	42.1
16	0.48	30.0	0.64	40.0
18	0.52	28.9	0.69	38.3
20	0.56	28.0	0.74	37.0
25	0.65	26.0	0.86	34.4
30	0.73	24.3	0.98	32.7
35	0.81	23.1	1.08	30.9
40	0.89	22.2	1.18	29.5
50	1.03	20.6	1.37	27.4
60	1.16	19.3	1.55	25.8
70	1.29	18.4	1.72	24.6
80	1.41	17.6	1.88	23.5
90	1.52	16.9	2.03	22.6
100	1.63	16.3	2.18	21.8

For premedication:

10-40 µg medetomidine hydrochloride per kg body weight, corresponding to 0.1-0.4 ml per 10 kg body weight. The exact dose depends on the combination of drugs used and the dosage(s) of the other drug(s). The dose should furthermore be adjusted to the type of surgery, length of procedure and patient temperament and weight. Premedication with medetomidine will significantly reduce the dosage of the

induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect. Before using any combinations, product literature for the other veterinary medicinal products should be observed. See also section 3.5.

Cats: intramuscular, intravenous and subcutaneous use

For moderate-deep sedation and restraint of cats the veterinary medicinal product should be administered at a dosage of 50 – 150 µg medetomidine hydrochloride /kg bw (corresp. to 0.05 – 0.15 ml/ kg bw). The speed of induction is slower when subcutaneous route of administration is used.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In cases of overdosage, the principal signs are prolonged anaesthesia or sedation. In some cases, cardiorespiratory effects may occur. The treatment consists of the administration of an alpha-2 antagonist, as atipamezole, provided that reversal of sedation is not dangerous for the animal (atipamezole does not reverse the effects of ketamine, which used alone can produce convulsions in dogs and cramps in cats). Alpha-2-antagonists should not be given less than 30-40 minutes after the administration of ketamine.

Atipamezole hydrochloride is administered by intramuscular route at the following dosage: 5 times the initial dose of medetomidine hydrochloride administered to dogs (µg/kg) and 2.5 times for cats. The volume of atipamezole hydrochloride 5 mg/ml is equal to volume of drug administered to dogs; for cats half of this volume should be used.

If it is imperative to reverse bradycardia but to maintain sedation, atropine may be used.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

To be completed nationally.

ES: <For administration only by a veterinarian>

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QN05CM91

4.2 Pharmacodynamics

Medetomidine is a sedative component which presents analgesic and myorelaxant properties. It is a selective agonist, specific and particularly effective for alpha-2-adrenergic receptors. The activation of these receptors induces a decrease in the release and turnover of noradrenalin in central nervous system which is declared by means of sedation, analgesia and bradycardia. At peripheral level, medetomidine causes vasoconstriction by stimulation of post-synaptic alpha-2-adrenergic receptors, which produce a transitory hypertension. Blood pressure returns to normal levels, even to a moderate hypotension within 1 to 2 hours. Respiratory rate can be reduced temporarily.

The time and depth of sedation and analgesia are dose dependent. When the effect is maximum, the animal is relaxed and does not respond to external stimulation. Medetomidine acts in a synergic manner with ketamine or opiates, such as fentanyl, resulting in a better anaesthesia. The necessary amount of volatile anaesthetics (e.g. halothane) is reduced by medetomidine. In addition to its sedative, analgesia

and myorelaxant properties, medetomidine also exerts hypothermic and mydriatic effects, inhibits the salivation and decreases intestinal motility.

4.3 Pharmacokinetics

After intramuscular injection, medetomidine is rapidly and almost completely absorbed in the site of injection and pharmacokinetics is very similar to that observed after intravenous injection. Maximum plasma concentrations are reached within 15 to 20 minutes. Estimated plasma half-life is 1.2 hours for dogs and 1.5 hours for cats. Medetomidine is mainly oxidised in the liver, while a small amount is methylated in the kidney. Metabolites are primarily excreted in urine.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life after first opening the immediate packaging: 28 days.

5.3 Special precautions for storage

Do not refrigerate or freeze.

Protect from light.

Protect from frost.

5.4 Nature and composition of immediate packaging

10 ml Type I clear glass vial, fitted with a bromobutyl stopper and sealed with an aluminium cap, in a cardboard box.

Package size:

Cardboard box with 1 vial of 10 ml

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Azienda Terapeutica Italiana A.T.I. s.r.l.

7. MARKETING AUTHORISATION NUMBER(S)

To be completed nationally.

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: DD/MM/YYYY.

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

MM/YYYY

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box: 1 vial of 10 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dormisan 1 mg/ml solution for injection for dogs and cats [ES, IT]
Sedalgan 1 mg/ml solution for injection for dogs and cats [PT]

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

medetomidine hydrochloride	1.0 mg
(medetomidine	0.85 mg)

3. PACKAGE SIZE

10 ml

4. TARGET SPECIES

Dogs and cats.

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Dogs: for intramuscular or intravenous use
Cats: for subcutaneous, intramuscular or intravenous use

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}
Once broached use within 28 days
Use by

9. SPECIAL STORAGE PRECAUTIONS

Do not refrigerate or freeze.
Protect from light.
Protect from frost.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Azienda Terapeutica Italiana A.T.I. s.r.l.

14. MARKETING AUTHORISATION NUMBERS

To be completed nationally.

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

10 ml label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dormisan [ES, IT]

Sedalgan [PT]

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

medetomidine hydrochloride	1.0 mg/ml
(medetomidine	0.85 mg/ml)

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 28 days

Use by

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Dormisan 1 mg/ml solution for injection for dogs and cats [ES, IT]

Sedalgan 1 mg/ml solution for injection for dogs and cats [PT]

2. Composition

Each ml contains:

Active substance:

medetomidine hydrochloride	1.0 mg
(equivalent to medetomidine	0.85 mg)

Excipients:

methyl parahydroxybenzoate (E218)	1.0 mg
propyl parahydroxybenzoate	0.2 mg

Clear and colourless solution.

3. Target species

Dogs and cats.

4. Indications for use

In dogs and cats:

- Sedation in order to facilitate the restraint of animals during clinical examinations.
- Premedication prior to general anaesthesia.

5. Contraindications

Do not use in animals with serious cardiovascular disease, respiratory disease or hepatic or renal disorders.

Do not use in case of mechanical disorders of gastrointestinal tract (torsion of the stomach, imprisonment, obstruction of the oesophagus).

Do not use in conjunction with sympathomimetic amines.

Do not use in cases of hypersensitivity to the active substance or any excipients.

Do not use in animals with diabetes mellitus.

Do not use in animals with state of shock, emaciation or serious debilitation.

Do not use in animals with ocular problems where an increase in intraocular pressure would be detrimental.

Do not use in animal with decreased liver function.

See section 6 "Pregnancy and lactation".

6. Special warnings

Special warnings:

It is possible that medetomidine does not provide analgesia throughout the entire sedation period. The use of additional analgesics should be considered during painful surgical procedures.

Special precautions for safe use in the target species:

A clinical examination should be carried out in all animals before the use of veterinary medicinal products for sedation and/or general anaesthesia.

During its use in premedication, the dosage of anaesthetic will be reduced in proportion and established according to the reaction of the animal, depending on the variability of response between animals. Special warnings and contraindications included in the literature of the other veterinary medicinal products should be respected before carrying out any association.

Medetomidine can produce respiratory depression; in such case, manual ventilation and administration of oxygen may be conducted.

Higher doses of medetomidine should be avoided in large breed dogs. Care should be taken when combining medetomidine with other anaesthetics or sedatives because of its marked anaesthetic sparing effects. Animals should be fasted 12 hours before anaesthesia.

The animal should be placed in a calm and quiet surrounding to let the sedation gain its maximum effect. This takes about 10-15 minutes. One should not start any procedure or give other veterinary medicinal products before maximum sedation is reached.

Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.

The eyes should be protected by a suitable lubricant.

Nervous, aggressive or excited animals should be given the possibility to calm down before initiation of treatment.

Sick and debilitated dogs and cats should only be premedicated with medetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.

Care should be taken with use of medetomidine in animals with cardiovascular disease, or which are elderly or in general poor health. Liver and kidney function should be evaluated prior to use.

In order to reduce the recovery time after anaesthesia or sedation, the effect of medetomidine can be reversed by the administration of an alpha-2-antagonist such as atipemazole.

Atipemazole does not reverse the effect of ketamine. As ketamine alone can elicit cramps, alpha-2 antagonists should not be given less than 30-40 min. after the administration of ketamine.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Medetomidine is a sedative and sleep-inducing drug. Care should be taken to avoid self-injection. In the case of accidental ingestion or self-injection, seek medical advice immediately and show the package insert to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur.

Avoid skin, eye or mucosal contact.

In case of skin or mucosal contact, wash the exposed skin immediately after exposure with large amounts of water.

Remove contaminated clothes that are in direct contact with skin.

In the case of accidental contact of the veterinary medicinal product with eyes, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.

Pregnant women should administer the product with special caution to avoid self-injection since uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.

Advice to doctors:

Medetomidine is an alpha2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported.

Respiratory and haemodynamic symptoms should be treated symptomatically.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore, do not use during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

The concomitant administration of other central nervous system depressants should be expected to potentiate the effect of either veterinary medicinal product and appropriate dose adjustment should be made.

Medetomidine has marked anaesthetic sparing effects (see Special precautions).

The effects of medetomidine can be antagonised by the administration of atipamezole.

Do not administer concomitantly with sympathomimetics or sulfamides and trimethoprim.

Overdose:

In cases of overdosage, the principal signs are prolonged anaesthesia or sedation. In some cases, cardiorespiratory effects may occur. The treatment consists of the administration of an alpha-2 antagonist, as atipamezole, provided that reversal of sedation is not dangerous for the animal (atipamezole does not reverse the effects of ketamine, which used alone can produce convulsions in dogs and cramps in cats). Alpha-2-antagonists should not be given less than 30-40 minutes after the administration of ketamine.

Atipamezole hydrochloride is administered by intramuscular route at the following dosage: 5 times the initial dose of medetomidine hydrochloride administered to dogs ($\mu\text{g}/\text{kg}$) and 2.5 times for cats. The volume of atipamezole hydrochloride 5 mg/ml is equal to volume of drug administered to dogs; for cats half of this volume should be used.

If it is imperative to reverse bradycardia but to maintain sedation, atropine may be used.

Special restrictions for use and special conditions for use:

Not applicable.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Dogs and cats:

Undetermined frequency (cannot be estimated from the available data)*	Bradycardia, heart block 1 st degree, heart block 2 nd degree, extrasystole, vasoconstriction of coronary artery, decreased cardiac output ^a , high blood pressure ^b . Vomiting ^c . Increased sensitivity to sound, tremor. Frequent urination. Hypothermia, cyanosis. Respiratory depression ^a , pulmonary oedema. Injection site pain. Hyperglycaemia ^d .
---	---

^a in cases of cardiovascular and respiratory depression, assisted ventilation and administration of oxygen may be indicated. Atropine can increase the cardiac rate.

^b just after the administration of product and then return to the normal value or slightly below.

^c in some dogs and most cats 5-10 minutes after injection. Cats may also vomit on recovery.

^d reversible, due to depression of insulin secretion.

*Dogs weighing less than 10 kg can present frequently with the above-mentioned adverse reactions.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: { national system details }

8. Dosage for each species, routes and method of administration

Dogs: intramuscular or intravenous use

For sedation:

For sedation the veterinary medicinal product should be administered at the rate of 15-80 µg of medetomidine hydrochloride per kg of body weight I.V., or 20-100 µg of medetomidine hydrochloride per kg of body weight I.M.

Use the table below to determine the correct dosage on the basis of body weight.

Maximal effect is obtained within 15-20 minutes. Clinical effect is dose-dependent, lasting 30 to 180 minutes.

The veterinary medicinal product dosages in ml and corresponding amount of medetomidine hydrochloride in µg /kg bw:

body weight [kg]	i.v.- Injection		i.m.- Injection	
	[ml]	corresp. to [µg/kg bw]	[ml]	corresp. to [µg/kg bw]
1	0.08	80.0	0.10	100.0
2	0.12	60.0	0.16	80.0
3	0.16	53.3	0.21	70.0
4	0.19	47.5	0.25	62.5
5	0.22	44.0	0.30	60.0
6	0.25	41.7	0.33	55.0
7	0.28	40.0	0.37	52.9
8	0.30	37.5	0.40	50.0
9	0.33	36.7	0.44	48.9
10	0.35	35.0	0.47	47.0
12	0.40	33.3	0.53	44.2
14	0.44	31.4	0.59	42.1
16	0.48	30.0	0.64	40.0
18	0.52	28.9	0.69	38.3
20	0.56	28.0	0.74	37.0
25	0.65	26.0	0.86	34.4
30	0.73	24.3	0.98	32.7
35	0.81	23.1	1.08	30.9
40	0.89	22.2	1.18	29.5
50	1.03	20.6	1.37	27.4
60	1.16	19.3	1.55	25.8
70	1.29	18.4	1.72	24.6
80	1.41	17.6	1.88	23.5
90	1.52	16.9	2.03	22.6
100	1.63	16.3	2.18	21.8

For premedication:

10-40 µg medetomidine hydrochloride per kg body weight, corresponding to 0.1-0.4 ml per 10 kg body weight. The exact dose depends on the combination of drugs used and the dosage(s) of the other drug(s). The dose should furthermore be adjusted to the type of surgery, length of procedure and patient temperament and weight. Premedication with medetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect. Before using any combinations, product literature for the other products should be observed. See also section 12 "Special precautions for use in animals".

Cats: intramuscular, intravenous and subcutaneous use

For moderate-deep sedation and restraint of cats the veterinary medicinal product should be administered at a dosage of 50 – 150 µg medetomidine hydrochloride /kg bw (corresp. to 0.05 – 0.15 ml/ kg bw). The speed of induction is slower when subcutaneous route of administration is used.

9. Advice on correct administration

None.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not refrigerate or freeze.

Protect from light.

Protect from frost.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicine no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Package size:

Cardboard box with 1 vial of 10 ml

15. Date on which the package leaflet was last revised

MM/YYYY

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder:

Azienda Terapeutica Italiana A.T.I. s.r.l.
Via Emilia, 285
40064 - Ozzano dell'Emilia (BO)
Italy

Manufacturer responsible for batch release:

Industrial Veterinaria, S.A.
Esmeralda, 19
08950 Esplugues de Llobregat (Barcelona)
Spain

Chemical Iberica PV, S.L.
Ctra. Burgos-Portugal, Km. 256
37448 Calzada de Don Diego (Salamanca)
Spain

Local representatives and contact details to report suspected adverse reactions:

To be completed nationally.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.